What to watch for in the crucial FDA meeting on MDMA therapy for PTSD
In less than three months, the Food and Drug Administration will decide whether to approve MDMA as the first new treatment for post-traumatic stress disorder in more than two decades.
It’s a landmark moment for advocates of using psychedelics as treatments for psychiatric disorders: If approved, MDMA would be the first Schedule I psychedelic — classified by the government as having high potential for abuse and no medical benefit — to be found to actually have a medical use. More psychedelics are in the pipeline, with Phase 3 trials underway on psilocybin for treatment-resistant depression, and smaller studies on psychedelics including DMT, ibogaine, and LSD as treatments for a range of conditions, including anorexia, addiction, and autism.
Read Original Article: What to watch for in the crucial FDA meeting on MDMA therapy for PTSD »
